Key role of CRF in the skin stress response system

Endocrine Reviews

Volumn 34, Issue 6, 2013, Pages 827-884

  Slominski, Andrzej T ^a   Zmijewski, Michal A ^b   Zbytek, Blazej ^a   Tobin, Desmond J ^c   Theoharides, Theoharis C ^d   Rivier, Jean ^e  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYTOKINE; HUMORAL ANTIBODY; INTERMEDIN; NEUROPEPTIDE; PROOPIOMELANOCORTIN; UROCORTIN; UROCORTIN I; UROCORTIN II; UROCORTIN III;

ALOPECIA; ALTERNATIVE RNA SPLICING; CARDIOVASCULAR SYSTEM; CELL TYPE; DERMIS; EMOTIONAL STRESS; ENVIRONMENTAL STRESS; FIBROBLAST; GASTROINTESTINAL TRACT; GENE STRUCTURE; GESTATIONAL SAC; HAIR FOLLICLE; HAIR GROWTH; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; KERATINOCYTE; MELANOCYTE; MELANOMA; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY MECHANISM; REVIEW; SEBACEOUS GLAND; SENSORY NERVE; SIGNAL TRANSDUCTION; SKIN; SKIN FLORA; SKIN FUNCTION; SKIN PIGMENTATION; STRESS; SWEAT GLAND; ULTRAVIOLET RADIATION; VITILIGO;

ALTERNATIVE SPLICING; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; ENVIRONMENT; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SKIN; SKIN PHYSIOLOGICAL PHENOMENA; STRESS, PHYSIOLOGICAL; UROCORTINS;

EID: 84887829127     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2012-1092     Document Type: Review

References (609)

1. Selye H. A syndrome produced by diverse noxious agents. Nature. 1936;138:32-33.
2. Selye H. The Stress of Life, revised ed. New York, NY: McGraw-Hill Book Company; 1976.
3. Spiess J, Rivier J, Rivier C, Vale W. Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci USA. 1981;78:6517-6521.
4. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science. 1981; 213:1394-1397.
5. Harris GW. Neural control of the pituitary gland. Physiol Rev. 1948;28:139-179.
6. R, Rosenberg B. Humoral hypothalamic control of anterior pituitary: a study with combined tissue cultures. Endocrinology. 1955;57:599-607.
7. Saffran M, Schally AV. The release of corticotrophin by anterior pituitary tissue in vitro. Can J Biochem Physiol. 1955;33:408-415.
8. Vale W, Grant G, Amoss M, Blackwell R, Guillemin R. Culture of enzymatically dispersed pituitary cells: functional validation of a method. Endocrinology. 1972;91: 562-572.
9. Burgus R, Dunn TF, Desiderio D, Ward DN, Vale W, Guillemin R. Characterization of ovine hypothalamic hypophysiotropic TSH-releasing factor. Nature. 1970;226:321-325.
10. Schally AV, ReddingTW,Bowers CY, Barrett JF. Isolation and properties of porcine thyrotropin-releasing hormone. J Biol Chem. 1969;244:4077-4088.
11. Baba Y, Matsuo H, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses. Biochem Biophys Res Commun. 1971;44:459-463.
12. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77-79.
13. Burgus R, Rivier J. Use of high pressure liquid chromatography in the purification of peptides. In: Loffet A, ed. Peptides 1976. Bruxelles, Belgium: Editions de l'Universite de Bruxelles; 1976:85-94.
14. Rivier J. Use of trialkyl ammonium phosphate (TAAP) buffers in reverse phase HPLC for high resolution and high recovery of peptides and proteins. J Liq Chromatog. 1978; 1:343-366.
15. Bennett HPJ, Browne CA, Solomon S. The use of perfluorinated carboxylic acids in the reversed-phase HPLC of peptides. J Liq Chromatog. 1980;3:1353-1365.
16. Rivier J, Spiess J, Vale W. Characterization of rat hypothalamic corticotropin-releasing factor. Proc Natl Acad Sci USA. 1983;80:4851-4855.
17. Furutani Y, Morimoto Y, Shibahara S, et al. Cloning and sequence analysis of cDNA for ovine corticotorpin-releasing factor precursor. Nature. 1983;301:537-540.
18. Montecucchi PC, Anastasi A, de Castiglione R, Erspamer V. Isolation and amino acid composition of sauvagine. An active polypeptide from methanol extracts of the skin of the South American frog Phyllomedusa sauvagei. Int J Pept Protein Res. 1980;16:191-199.
19. Lederis K, Letter A, McMaster D, Moore G, Schlesinger D. Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. Science. 1982;218:162-165.
20. Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 2001;98:7570-7575.
21. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA. 2001;98:2843-2848.
22. Chang CP, PearseRVII, O'Connell S, RosenfeldMG.Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron. 1993;11:1187-1195.
23. ChenR, LewisKA,PerrinMH,ValeWW. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA. 1993;90:8967-8971.
24. Vita N, Laurent P, Lefort S, et al. Primary structure and functional expression of mouse pituitary and human brain corticotropin releasing factor receptors. FEBS Lett. 1993; 335:1-5.
25. Kishimoto T, Pearse RV II, Lin CR, Rosenfeld MG. A sauvagine/ corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA. 1995; 92:1108-1112.
26. Lovenberg TW, Liaw CW, Grigoriadis DE, et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA. 1995;92:836-840.
27. Perrin M, Donaldson C, Chen R, et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA. 1995;92:2969-2973.
28. Stenzel P, Kesterson R, Yeung W, Cone RD, Rittenberg MB, Stenzel-Poore MP. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol. 1995;9:637-645.
29. Kostich WA, Chen A, Sperle K, Largent BL. Molecular identification and analysis of a novel human corticotropinreleasing factor (CRF) receptor: the CRF2 γ receptor. Mol Endocrinol. 1998;12:1077-1085.
30. Cannon WB. Bodily Changes in Pain, Hunger, Fear and Rage. New York, NY: Appleton-Century-Crofts; 1929.
31. Furness JB. The organisation of the autonomic nervous system: peripheral connections. Auton Neurosci. 2006; 130:1-5.
32. O'Connor TM, O'Halloran DJ, Shanahan F. The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. QJM. 2000;93:323-333.
33. Kaltschmidt B, Widera D, Kaltschmidt C. Signaling via NF-κ Binthe nervous system. Biochim Biophys Acta. 2005; 1745:287-299.
34. Delves PJ, Roitt IM. Theimmunesystem. First of two parts. N Engl J Med. 2000;343:37-49.
35. Blalock JE, Smith EM. Conceptual development of the immune system as a sixth sense. Brain Behav Immun. 2007; 21:23-33.
36. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006;8:383-395.
37. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374-381.
38. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155-1228.
39. Mazon AF, Verburg-van Kemenade BM, Flik G, Huising MO. Corticotropin-releasing hormone-receptor 1 (CRHR1) and CRH-binding protein (CRH-BP) are expressed in the gills and skin of common carp Cyprinus carpio L. and respond to acute stress and infection. J Exp Biol. 2006; 209:510-517.
40. Slominski A, Wortsman J, Paus R, Elias PM, Tobin DJ, Feingold KR. Skin as an endocrine organ: implications for its function. Drug Discov Today Dis Mech. 2008;5:137-144.
41. Alderman SL, Bernier NJ. Ontogeny of the corticotropinreleasing factor system in zebrafish. Gen Comp Endocrinol. 2009;164:61-69.
42. Roulin A, Emaresi G, Bize P, Gasparini J, Piault R, Ducrest AL. Pale and dark reddish melanic tawny owls differentially regulate the level of blood circulating POMC prohormone in relation to environmental conditions. Oecologia. 2011;166:913-921.
43. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation.NEngl J Med. 1995; 332:1351-1362.
44. Karalis K, Muglia LJ, Bae D, Hilderbrand H, Majzoub JA. CRH and the immune system. J Neuroimmunol. 1997;72: 131-136.
45. Kempuraj D, Papadopoulou NG, Lytinas M, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology. 2004;145:43-48.
46. Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In: Fisher S, Reason J, eds. Handbook of Life Stress, Cognition and Health. New York, NY: Wiley; 1988:629-649.
47. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007; 87:873-904.
48. McEwen BS. Brain on stress: How the social environment gets under the skin. Proc Natl Acad Sci USA. 2012; 109(suppl 2):17180-17185.
49. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol. 2012; 212:5, 7, 1-115.
50. Uniprot Web site. http://www.uniprot.org. 2012.
51. SABiosciences Web site. EpiTect ChIP qPCR Primers. http://www.sabiosciences.com/chipqpcrsearch.php?species_id_0&nfactor_n&ninfo_n&ngene_n&B2_ Search&src_genecard&factor_Over_200_TF&gene_ CRH. 2012.
52. GeneCards Web site. http://www.genecards.org/cgi-bin/carddisp.pl?gene_UCN3&search_Urocortin. 2012.
53. NCBI Web site. http://www.ncbi.nlm.nih.gov/homologene/. 2012.
54. Karteris E, Grammatopoulos D, Dai Y, et al. The human placenta and fetal membranes express the corticotropinreleasing hormone receptor 1α (CRH-1α) and the CRH-C variant receptor. J Clin Endocrinol Metab. 1998;83:1376-1379.
55. Slominski A, Wortsman J, Pisarchik A, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J. 2001;15:1678-1693.
56. Jin D, He P, You X, et al. Expression of corticotropinreleasing hormone receptor type 1 and type 2 in human pregnant myometrium. Reprod Sci. 2007;14:568-577.
57. Gay J, Kokkotou E, O'Brien M, Pothoulakis C, Karalis KP. Corticotropin-releasing hormone deficiency is associated with reduced local inflammation in a mouse model of experimental colitis. Endocrinology. 2008;149:3403-3409.
58. JensenLab Web site. http://diseases.jensenlab.org/Search. 2012.
59. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol. 2006;27:32-39.
60. Cao J, BoucherW,Kempuraj D, Donelan JM, Theoharides TC. Acute stress and intravesical corticotropin-releasing hormone induces mast cell dependent vascular endothelial growth factor release from mouse bladder explants. J Urol. 2006;176:1208-1213.
61. Theoharides TC, Whitmore K, Stanford E, Moldwin R, O'Leary MP. Interstitial cystitis: bladder pain and beyond. Expert Opin Pharmacother. 2008;9:2979-2994.
62. Angelidou A, Asadi S, Alysandratos KD, Karagkouni A, Kourembanas S, Theoharides TC. Perinatal stress, brain inflammation and risk of autism-review and proposal. BMC Pediatr. 2012;12:89.
63. Lovejoy DA, Balment RJ. Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates. Gen Comp Endocrinol. 1999;115: 1-22.
64. Lovejoy DA, Rotzinger S, Barsyte-Lovejoy D. Evolution of complementary peptide systems: teneurin C-terminalassociated peptides and corticotropin-releasing factor superfamilies. Ann NY Acad Sci. 2009;1163:215-220.
65. Chand D, Lovejoy DA. Stress and reproduction: controversies and challenges. Gen Comp Endocrinol. 2011;171: 253-257.
66. Miller LJ,DongM,HarikumarKG,GaoF. Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor. Biochem Soc Trans. 2007;35:709-712.
67. Markovic D, Grammatopoulos DK. Focus on the splicing of secretin GPCRs transmembrane-domain 7. Trends Biochem Sci. 2009;34:443-452.
68. LagerstromMC,Schioth HB. Structural diversity ofGprotein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov. 2008;7:339-357.
69. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann NY Acad Sci. 1999; 885:312-328.
70. Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev. 2006;27:260-286.
71. Hillhouse EW, Randeva H, Ladds G, Grammatopoulos D. Corticotropin-releasing hormone receptors. Biochem Soc Trans. 2002;30:428-432.
72. Hemley CF, McCluskey A, Keller PA. Corticotropin releasing hormone-a GPCR drug target. Curr Drug Targets. 2007;8:105-115.
73. Grammatopoulos DK. Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br J Pharmacol. 2012;166:85-97.
74. Arzt E, Holsboer F. CRF signaling: molecular specificity for drug targeting in the CNS. Trends Pharmacol Sci. 2006; 27:531-538.
75. Justice NJ, Yuan ZF, Sawchenko PE, Vale W. Type 1 corticotropin-releasing factor receptor expression reported in BAC transgenic mice: implications for reconciling ligandreceptor mismatch in the central corticotropin-releasing factor system. J Comp Neurol. 2008;511:479-496.
76. Kuhne C, Puk O, Graw J, et al. Visualizing corticotropinreleasing hormone receptor type 1 expression and neuronal connectivities in the mouse using a novel multifunctional allele. J Comp Neurol. 2012;520:3150-3180.
77. Van Pett K, Viau V, Bittencourt JC, et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol. 2000;428:191-212.
78. Graham CE, Vetter DE. The mouse cochlea expresses a local hypothalamic-pituitary-adrenal equivalent signaling system and requires corticotropin-releasing factor receptor 1 to establish normal hair cell innervation and cochlear sensitivity. J Neurosci. 2011;31:1267-1278.
79. Kiapekou E, Zapanti E, Mastorakos G, Loutradis D. Update on the role of ovarian corticotropin-releasing hormone. Ann NY Acad Sci. 2010;1205:225-229.
80. Slominski A, Zbytek B, Zmijewski M, et al. Corticotropin releasing hormone and the skin. Front Biosci. 2006;11: 2230-2248.
81. Zmijewski MA, Slominski AT. Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim Pol. 2010;57:1-13.
82. Grammatopoulos DK. Placental corticotrophin-releasing hormone and its receptors inhumanpregnancy and labour: still a scientific enigma. J Neuroendocrinol. 2008;20:432-438.
83. Kokkotou E, Torres D, Moss AC, et al. Corticotropinreleasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol. 2006;177: 3355-3361.
84. Larauche M, Kiank C, TachéY. Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications. J Physiol Pharmacol. 2009;60(suppl 7):33-46.
85. TachéY, Kiank C, Stengel A. A role for corticotropinreleasing factor in functional gastrointestinal disorders. Curr Gastroenterol Rep. 2009;11:270-277.
86. Wallon C, Söderholm JD. Corticotropin-releasing hormone and mast cells in the regulation of mucosal barrier function in the human colon. Ann NY Acad Sci. 2009; 1165:206-210.
87. Yang LZ, Tovote P, Rayner M, Kockskamper J, Pieske B, Spiess J. Corticotropin-releasing factor receptors and urocortins, links between the brain and the heart. Eur J Pharmacol. 2010;632:1-6.
88. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev. 2003;55:21-26.
89. Jonassen AK, Wergeland A, Helgeland E, Mjos OD, Brar BK. Activation of corticotropin releasing factor receptor type 2 in the heart by corticotropin releasing factor offers cytoprotection against ischemic injury via PKA and PKC dependent signaling. Regul Pept. 2012;174:90-97.
90. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol. 2005;174:7665-7675.
91. Takahashi K. Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system. Int J Endocrinol. 2012;2012:395284.
92. Schöneberg T, Hofreiter M, Schulz A, Römpler H. Learning from the past: evolution of GPCR functions. Trends Pharmacol Sci. 2007;28:117-121.
93. Lovejoy DA, Jahan S. Phylogeny of the corticotropinreleasing factor family of peptides in the metazoa. Gen Comp Endocrinol. 2006;146:1-8.
94. Denver RJ. Structural and functional evolution of vertebrate neuroendocrine stress systems. Ann NY Acad Sci. 2009;1163:1-16.
95. Campbell RK, Satoh N, Degnan BM. Piecing together evolution of the vertebrate endocrine system. Trends Genet. 2004;20:359-366.
96. Polymeropoulos MH, Torres R, Yanovski JA, Chandrasekharappa SC, Ledbetter DH. The human corticotropin-releasing factor receptor (CRHR) gene maps to chromosome 17q12-q22. Genomics. 1995;28:123-124.
97. Tsai-Morris CH, Buczko E, Geng Y, Gamboa-Pinto A, Dufau ML. The genomic structure of the rat corticotropin releasing factor receptor. A member of the class II G protein-coupled receptors. J Biol Chem. 1996;271:14519-14525.
98. Sakai K, Yamada M, Horiba N, Wakui M, Demura H, Suda T. The genomic organization of the human corticotropin-releasing factor type-1 receptor. Gene. 1998;219: 125-130.
99. Parham KL, Zervou S, Karteris E, Catalano RD, Old RW, Hillhouse EW. Promoter analysis of human corticotropinreleasing factor (CRF) type 1 receptor and regulation by CRF and urocortin. Endocrinology. 2004;145:3971-3983.
100. Perrin MH, Fischer WH, Kunitake KS, et al. Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor. J Biol Chem. 2001;276: 31528-31534.
101. Pioszak AA, Parker NR, Suino-Powell K, Xu HE. Molecular recognition of corticotropin-releasing factor by its Gprotein-coupled receptor CRFR1. J Biol Chem. 2008;283: 32900-32912.
102. Grace CR, Perrin MH, Gulyas J, Rivier JE, ValeWW,Riek R. NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist. J Biol Chem. 2010; 285:38580-38589.
103. Perrin MH, Grace CR, Riek R, Vale WW. The threedimensional structure of the N-terminal domain of corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors. Ann NY Acad Sci. 2006;1070:105-119.
104. Arai M, Assil IQ, Abou-Samra AB. Characterization of three corticotropin-releasing factor receptors in catfish: a novel third receptor is predominantly expressed in pituitary and urophysis. Endocrinology. 2001;142:446-454.
105. Hofmann BA, Sydow S, Jahn O, et al. Functional and protein chemical characterization of the N-terminal domain of the rat corticotropin-releasing factor receptor 1. Protein Sci. 2001;10:2050-2062.
106. Sydow S, Radulovic J, Dautzenberg FM, Spiess J. Structure-function relationship of different domains of the rat corticotropin-releasing factor receptor. Brain Res Mol Brain Res. 1997;52:182-193.
107. Assil IQ, Abou-Samra AB. N-glycosylation of CRF receptor type 1 is important for its ligand-specific interaction. Am J Physiol Endocrinol Metab. 2001;281:E1015-E1021.
108. Duvernay MT, Filipeanu CM, Wu G. The regulatory mechanisms of export trafficking of G protein-coupled receptors. Cell Signal. 2005;17:1457-1465.
109. Zmijewski MA, Slominski AT. CRF1 receptor splicing in epidermal keratinocytes: potential biological role and environmental regulations. J Cell Physiol. 2009;218:593-602.
110. Pal K, Swaminathan K, Xu HE, Pioszak AA. Structural basis for hormone recognition by the human CRFR2α G protein-coupled receptor. J Biol Chem. 2010;285:40351-40361.
111. Pisarchik A, Slominski AT. Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J. 2001;15:2754-2756.
112. Pisarchik A, Slominski A. Corticotropin releasing factor receptor type 1: molecular cloning and investigation of alternative splicing in the hamster skin. J Invest Dermatol. 2002;118:1065-1072.
113. Slominski AT, Zmijewski MA, Pisarchik A, Wortsman J. Molecular cloning and initial characterization of African green monkey (Cercopithecus aethiops) corticotropin releasing factor receptor type 1 (CRF1) from COS-7 cells. Gene. 2007;389:154-162.
114. Grammatopoulos DK, Dai Y, Randeva HS, et al. A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol. 1999;13: 2189-2202.
115. Seck T, Pellegrini M, Florea AM, et al. The {rectangle opene13 isoform of the calcitonin receptor forms a six-transmembrane domain receptor with dominant-negative effects on receptor surface expression and signaling. Mol Endocrinol. 2005; 19:2132-2144.
116. Markovic D, Lehnert H, Levine MA, Grammatopoulos DK. Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: lessons from the receptor variant R1d. Mol Endocrinol. 2008;22: 2505-2519.
117. Slominski A, Zbytek B, Pisarchik A, Slominski RM, Zmijewski MA, Wortsman J. CRH functions as a growth factor/ cytokine in the skin. J Cell Physiol. 2006;206:780-791.
118. Karteris E, Markovic D, Chen J, Hillhouse EW, Grammatopoulos DK. Identification of a novel corticotropinreleasing hormone type 1β-like receptor variant lacking exon 13 in human pregnant myometrium regulated by estradiol-17β and progesterone. Endocrinology. 2011;151: 4959-4968.
119. Wu SV, Yuan PQ, Lai J, et al. Activation of type 1 CRH receptor isoforms induces serotonin release from human carcinoid BON-1N cells: an enterochromaffin cell model. Endocrinology. 2011;152:126-137.
120. Grammatopoulos DK, Chrousos GP. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab. 2002;13:436-444.
121. Perrin MH, DiGruccio MR, Koerber SC, et al. A soluble form of the first extracellular domain of mouse type 2_ corticotropin-releasing factor receptor reveals differential ligand specificity. J Biol Chem. 2003;278:15595-15600.
122. Theoharides TC, Konstantinidou AD. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci. 2007;12:1615-1628.
123. Armario A. Activation of the hypothalamic-pituitary-adrenal axis by addictive drugs: different pathways, common outcome. Trends Pharmacol Sci. 2010;31:318-325.
124. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol. 2005;67:259-284.
125. Nader N, Chrousos GP, Kino T. Interactions of the circadianCLOCKsystem and theHPAaxis. Trends Endocrinol Metab. 2010;21:277-286.
126. Kino T. Circadian rhythms of glucocorticoid hormone actions in target tissues: potential clinical implications. Sci Signal. 2012;5:pt4.
127. Crumbley C, Wang Y, Kojetin DJ, Burris TP. Characterization of the core mammalian clock component, NPAS2, as a REV-ERBα/RORα target gene. J Biol Chem. 2010; 285:35386-35392.
128. Kino T, Chrousos GP. Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues. Mol Cell Endocrinol. 2011;336:23-30.
129. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev. 2000;21:457-487.
130. Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol. 2007;265-266:143-149.
131. Zmijewski MA, Sharma RK, Slominski AT. Expression of molecular equivalent of hypothalamic-pituitary-adrenal axis in adult retinal pigment epithelium. J Endocrinol. 2007;193:157-169.
132. Taves MD, Gomez-Sanchez CE, Soma KK. Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function. Am J Physiol Endocrinol Metab. 2011;301:E11-E24.
133. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 2nd ed. St Louis, MO: Mosby Elsevier 2008.
134. Elias PM, Choi EH. Interactions among stratum corneum defensive functions. Exp Dermatol. 2005;14:719-726.
135. Elias PM. The skin barrier as an innate immune element. Semin Immunopathol. 2007;29:3-14.
136. Feingold KR, Schmuth M, Elias PM. The regulation of permeability barrier homeostasis. J Invest Dermatol. 2007;127:1574-1576.
137. Elias PM, Menon G, Wetzel BK, Williams J. Barrier requirements as the evolutionary "driver" of epidermal pigmentation in humans.AmJ Hum Biol. 2010;22:526-537.
138. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001;81:449-494.
139. Zouboulis CC, Baron JM, Böhm M, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol. 2008;17:542-551.
140. Siemionow M, Gharb BB, Rampazzo A. The face as a sensory organ. Plast Reconstr Surg. 2011;127:652-662.
141. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86: 1309-1379.
142. Legat FJ, Wolf P. Cutaneous sensory nerves: mediators of phototherapeutic effects? Front Biosci (Landmark Ed). 2009;14:4921-4931.
143. Ahmad N, Mukhtar H. Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004;123:417-425.
144. Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol. 2006; 126:1948-1965.
145. Botchkarev VA, Yaar M, Peters EM, et al. Neurotrophins in skin biology and pathology. J Invest Dermatol. 2006; 126:1719-1727.
146. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin.HormMetab Res. 2007;39:85-95.
147. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res. 2008;49:499-509.
148. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/ melatoninergic system: securing a place under the sun. FASEB J. 2005;19:176-194.
149. Slominski A, Zmijewski MA, Pawelek J. L-Tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res. 2012; 25:14-27.
150. SlominskiA,ZmijewskiM,SemakI, et al. CytochromesP450 and skin cancer: role of local endocrine pathways Anticancer Agents Med Chem. doi:10.2174/18715206113139990308. [published online ahead of print July 16, 2013]
151. Slominski AT, Kim TK, Zmijewski MA, et al. Novel vitaminDphotoproducts and their precursors in the skin. Dermatoendocrinol. 2013;5:7-19.
152. Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions [published online ahead of print February 19, 2013]. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2013.02.006.
153. Eckert RL, Crish JF, Robinson NA. The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation. Physiol Rev. 1997;77:397-424.
154. Elias PM, Williams ML, Feingold KR. Abnormal barrier function in the pathogenesis of ichthyosis: therapeutic implications for lipid metabolic disorders. Clin Dermatol. 2012;30:311-322.
155. Chen WC, Zouboulis CC. Hormones and the pilosebaceous unit. Dermatoendocrinol. 2009;1:81-86.
156. Gilhar A, Etzioni A, Paus R. Alopecia areata.NEngl JMed. 2012;366:1515-1525.
157. Slominski A, Wortsman J, Plonka PM, Schallreuter KU, Paus R, Tobin DJ. Hair follicle pigmentation. J Invest Dermatol. 2005;124:13-21.
158. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity. 2011;35:857-869.
159. Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol. 2012;12:503-516.
160. Klein J, Permana PA, Owecki M, et al. What are subcutaneous adipocytes really good for? Exp Dermatol. 2007; 16:45-70.
161. ZmijewskiMA,Slominski AT. Neuroendocrinology of the skin: An overview and selective analysis. Dermatoendocrinol. 2011;3:3-10.
162. Slominski A, Paus R, Schadendorf D. Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol. 1993;164:103-120.
163. Slominski A. Neuroendocrine activity of the melanocyte. Exp Dermatol. 2009;18:760-763.
164. Schallreuter KU, Wood JM, Lemke R, et al. Production of catecholamines in the human epidermis. Biochem Biophys Res Commun. 1992;189:72-78.
165. Gillbro JM, Marles LK, Hibberts NA, Schallreuter KU. Autocrine catecholamine biosynthesis and the _-adrenoceptor signal promote pigmentation in human epidermal melanocytes. J Invest Dermatol. 2004;123:346-353.
166. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004;146:1-12.
167. Grando SA, Kist DA, Qi M, Dahl MV. Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol. 1993;101:32-36.
168. Grando SA. Cholinergic control of epidermal cohesion. Exp Dermatol. 2006;15:265-282.
169. Slominski A, FischerTW,ZmijewskiMA,et al. Onthe role of melatonin in skin physiology and pathology. Endocrine. 2005;27:137-148.
170. Fischer TW, Slominski A, Tobin DJ, Paus R. Melatonin and the hair follicle. J Pineal Res. 2008;44:1-15.
171. Fischer TW, Slominski A, Zmijewski MA, Reiter RJ, Paus R. Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp Dermatol. 2008; 17:713-730.
172. Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol Metab. 2008;19:17-24.
173. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351:152-166.
174. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000;80:979-1020.
175. Tobin DJ. Biochemistry of human skin-our brain on the outside. Chem Soc Rev. 2006;35:52-67.
176. Slominski A. Beta-endorphin/μ-opiate receptor system in the skin. J Invest Dermatol. 2003;120:12-13.
177. O'KaneM,MurphyEP, Kirby B. The role of corticotropinreleasing hormone in immune-mediated cutaneous inflammatory disease. Exp Dermatol. 2006;15:143-153.
178. Krause K, Schnitger A, Fimmel S, Glass E, Zouboulis CC. Corticotropin-releasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands. Horm Metab Res. 2007;39:166-170.
179. Slominski A, Pisarchik A, Semak I, et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J. 2002;16:896-898.
180. Slominski A, Zjawiony J, Wortsman J, et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem. 2004;271:4178-4188.
181. Slominski A, Wortsman J, Kohn L, et al. Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol. 2002;119:1449-1455.
182. van Beek N, BodóE, Kromminga A, et al. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. J Clin Endocrinol Metab. 2008;93:4381-4388.
183. Gáspár E, Hardenbicker C, BodóE, et al. Thyrotropin releasing hormone (TRH): a new player in human hairgrowth control. FASEB J. 2010;24:393-403.
184. Gaspar E, Nguyen-Thi KT, Hardenbicker C, et al. Thyrotropin-releasing hormone selectively stimulates human hair follicle pigmentation. J Invest Dermatol. 2011;131: 2368-2377.
185. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-QiM. Opioids and the skin-where do we stand? Exp Dermatol. 2009;18:424-430.
186. Slominski AT, Zmijewski MA, Zbytek B, et al. Regulated proenkephalin expression in human skin and cultured skin cells. J Invest Dermatol. 2011;131:613-622.
187. Biro T, Toth BI, Hasko G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009;30:411-420.
188. Slominski AT, Zmijewski MA, Semak I, et al. Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin. PLoS One. 2009;4:e4309.
189. Slominski A, Kim TK, Chen J, et al. 2012 Cytochrome P450scc-dependent metabolism of 7-dehydrocholesterol in placenta and epidermal keratinocytes. Int J Biochem Cell Biol. 2012;44:2003-2018.
190. Slominski AT, Kim TK, Shehabi HZ, et al. 2012 In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 2012;26:3901-3915.
191. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357:266-281.
192. Zmijewski MA, Li W, Zjawiony JK, et al. Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3_, 17_, 20-triol and their bioactivity in melanoma cells. Steroids. 2009;74:218-228.
193. Bikle DD. Vitamin D: an ancient hormone. Exp Dermatol. 2011;20:7-13.
194. Bikle DD. Vitamin D metabolism and function in the skin. Mol Cell Endocrinol. 2011;347:80-89.
195. BodóE, Kany B, Gaspar E, et al. Thyroid-stimulating hormone, a novel, locally produced modulator of human epidermal functions, is regulated by thyrotropin-releasing hormone and thyroid hormones. Endocrinology. 2010; 151:1633-1642.
196. Schallreuter KU, Lemke KR, Pittelkow MR, Wood JM, Korner C, Malik R. Catecholamines in human keratinocyte differentiation. J Invest Dermatol. 1995;104:953-957.
197. Grando SA. Biological functions of keratinocyte cholinergic receptors. J Investig Dermatol Symp Proc. 1997;2: 41-48.
198. Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions [published online ahead of print February 19, 2013]. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2013.02.006.
199. Slominski A, Wortsman J, Linton E, Pisarchik A, Zbytek B. The skin as a model for the immunomodulatory effects of corticotropin-releasing hormone. In: Schaefer M, Stein C, eds. Mind Over Matter-Regulation of Peripheral Inflammation by theCNS. Basel, Boston, Berlin: Birkhaeuser Verlag; 2003:149-176.
200. Slominski A. Onthe role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders. Br J Dermatol. 2009;160:229-232.
201. Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann NY Acad Sci. 2006;1088:78-99.
202. Slominski A, Ermak G, Hwang J, Chakraborty A, Mazurkiewicz JE, Mihm M. Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. FEBS Lett. 1995;374:113-116.
203. Slominski A, Baker J, Ermak G, Chakraborty A, Pawelek J. Ultraviolet B stimulates production of corticotropin releasing factor (CRF) by human melanocytes. FEBS Lett. 1996;399:175-176.
204. Slominski A, Ermak G, Mazurkiewicz JE, Baker J, Wortsman J. Characterization of corticotropin-releasing hormone (CRH) in human skin. J Clin Endocrinol Metab. 1998;83:1020-1024.
205. Funasaka Y, Sato H, Chakraborty AK, Ohashi A, Chrousos GP, Ichihashi M. Expression of proopiomelanocortin, corticotropin-releasing hormone (CRH), and CRH receptor in melanoma cells, nevus cells, and normal human melanocytes. J Investig Dermatol Symp Proc. 1999;4:105-109.
206. Kono M, Nagata H, Umemura S, Kawana S, Osamura RY. In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin(POMC)genes inhuman skin. FASEB J. 2001;15:2297-2299.
207. Zouboulis CC, Seltmann H, Hiroi N, et al. Corticotropinreleasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA. 2002;99:7148-7153.
208. Slominski A, Roloff B, Curry J, Dahiya M, Szczesniewski A, Wortsman J. The skin produces urocortin. J Clin Endocrinol Metab. 2000;85:815-823.
209. Slominski A, Pisarchik A, Tobin DJ, Mazurkiewicz JE, Wortsman J. Differential expression of a cutaneous corticotropin-releasing hormone system. Endocrinology. 2004; 145:941-950.
210. Slominski A, Szczesniewski A, Wortsman J. Liquid chromatography-mass spectrometry detection of corticotropin-releasing hormone and proopiomelanocortin-derived peptides in human skin. J Clin Endocrinol Metab. 2000; 85:3582-3588.
211. Slominski AT, Botchkarev V, Choudhry M, et al. Cutaneous expression of CRH and CRH-R. Is there a "skin stress response system?." Ann NY Acad Sci. 1999;885: 287-311.
212. Ito N, Ito T, Betterman A, Paus R. The human hair bulb is a source and target of CRH. J Invest Dermatol. 2004;122: 235-237.
213. Kauser S, Slominski A, Wei ET, Tobin DJ. Modulation of the human hair follicle pigmentary unit by corticotropinreleasing hormone and urocortin peptides. FASEB J. 2006; 20:882-895.
214. Zbytek B, Wortsman J, Slominski A. Characterization of a ultraviolet B-induced corticotropin-releasing hormoneproopiomelanocortin system in human melanocytes. Mol Endocrinol. 2006;20:2539-2547.
215. Kim JE, Cho DH, Kim HS, et al. Expression of the corticotropin-releasing hormone-proopiomelanocortin axis in the various clinical types of psoriasis.ExpDermatol. 2007; 16:104-109.
216. Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol. 2009;160:345-352.
217. Zhou C, Yu X, Cai D, Liu C, Li C. Role of corticotropinreleasing hormone and receptor in the pathogenesis of psoriasis. Med Hypotheses. 2009;73:513-515.
218. Vasiadi M, Therianou A, Sideri K, et al. Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis. J Allergy Clin Immunol. 2012;129:1410-1413.
219. Zbytek B, Slominski AT. CRH mediates inflammation induced by lipopolysaccharide in human adult epidermal keratinocytes. J Invest Dermatol. 2007;127:730-732.
220. Isard O, Knol AC, Castex-Rizzi N, Khammari A, Charveron M, Dreno B. Cutaneous induction of corticotropin releasing hormone by Propionibacterium acnes extracts. Dermatoendocrinol. 2009;1:96-99.
221. Skobowiat C, Dowdy JC, Sayre RM, Tuckey RC, Slominski A. Cutaneous hypothalamic-pituitary-adrenal axis homolog: regulation by ultraviolet radiation. Am J Physiol Endocrinol Metab. 2011;301:E484-E493.
222. Roloff B, Fechner K, Slominski A, et al. Hair cycle-dependent expression of corticotropin-releasing factor (CRF) andCRFreceptors in murine skin.FASEBJ. 1998;12:287-297.
223. Slominski A, Ermak G, Hwang J, Mazurkiewicz J, Corliss D, Eastman A. The expression of proopiomelanocortin (POMC) and of corticotropin releasing hormone receptor (CRH-R) genes in mouse skin. Biochim Biophys Acta. 1996;1289:247-251.
224. Chen A, Blount A, Vaughan J, Brar B, Vale W. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropinreleasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids. Endocrinology. 2004; 145:2445-2457.
225. Yamauchi N, Otagiri A, Nemoto T, et al. Distribution of urocortin 2 in various tissues of the rat. J Neuroendocrinol. 2005;17:656-663.
226. Chae JI, Ju SK, Lee MK, et al. cDNA cloning and analysis of tissue-specific gene expression of rat urocortin II [in Russian]. Mol Biol (Mosk). 2009;43:91-96.
227. Wu SV, Yuan PQ, Wang L, Peng YL, Chen CY, TachéY. Identification and characterization of multiple corticotropin-releasing factor type 2 receptor isoforms in the rat esophagus. Endocrinology. 2007;148:1675-1687.
228. HuangM,Berry J, Kandere K, LytinasM,Karalis K, Theoharides TC. Mast cell deficient W/W(v) mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. Int J Immunopathol Pharmacol. 2002;15:249-254.
229. Lytinas M, Kempuraj D, Huang M, Boucher W, Esposito P, Theoharides TC. Acute stress results in skin corticotropinreleasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int Arch Allergy Immunol. 2003; 130:224-231.
230. Zhang X, Yu M, Yu W, Weinberg J, Shapiro J, McElwee KJ. Development of alopecia areata is associated with higher central and peripheral hypothalamic-pituitary-adrenal tone in the skin graft induced C3H/HeJ mouse model. J Invest Dermatol. 2009;129:1527-1538.
231. Slominski AT, Roloff B, Zbytek B, et al. Corticotropin releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes. In Vitro Cell Dev Biol Anim. 2000;36:211-216.
232. Quevedo ME, Slominski A, Pinto W, Wei E, Wortsman J. Pleiotropic effects of corticotropin releasing hormone on normal human skin keratinocytes. In Vitro Cell Dev Biol Anim. 2001;37:50-54.
233. Asadi S, Alysandratos KD, Angelidou A, et al. Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol. 2012;132:324-329.
234. Flint MS, Morgan JB, Shreve SN, Tinkle SS. Restraint stress and corticotropin releasing hormone modulation of murine cutaneous POMC mRNA. Stress. 2003;6:59-62.
235. Kaneko K, Kawana S, Arai K, Shibasaki T. Corticotropinreleasing factor receptor type 1 is involved in the stressinduced exacerbation of chronic contact dermatitis in rats. Exp Dermatol. 2003;12:47-52.
236. Donelan J, Boucher W, Papadopoulou N, et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA. 2006;103:7759-7764.
237. Rassouli O, Liapakis G, Lazaridis I, et al. A novel role of peripheral corticotropin-releasing hormone(CRH)on dermal fibroblasts. PLoS One. 2011;6:e21654.
238. WangL, MillionM,Rivier J, et al.CRFreceptor antagonist astressin-B reverses and prevents alopecia in CRF overexpressing mice. PLoS One. 2011;6:e16377.
239. Tagen M, Stiles L, Kalogeromitros D, et al. Skin corticotropin-releasing hormone receptor expression in psoriasis. J Invest Dermatol. 2007;127:1789-1791.
240. Ito N, Sugawara K, BodóE, et al. Corticotropin-releasing hormone stimulates the in situ generation of mast cells from precursors in the human hair follicle mesenchyme. J Invest Dermatol. 2010;130:995-1004.
241. Donelan J, Marchand JE, Kempuraj D, Papadopoulou N, Papaliodis D, Theoharides TC. Perifollicular and perivascular mouse skin mast cells express corticotropin-releasing hormone receptor. J Invest Dermatol. 2006;126:929-932.
242. Katsarou-Katsari A, Singh LK, Theoharides TC. Alopecia areata and affected skin CRH receptor upregulation induced by acute emotional stress. Dermatology. 2001;203: 157-161.
243. Liu SJ, Xie YF, Dai LB, Du GW. Expression of secretions of hypothalamus-pituitary-adrenal axis in human hypertrophic scar [in Chinese]. Zhonghua Shao Shang Za Zhi. 2011;27:432-435.
244. Cemil BC, Canpolat F, Yilmazer D, Eskioglu F, Alper M. The association of PASI scores withCRH-R1expression in patients with psoriasis. Arch Dermatol Res. 2012;304: 127-132.
245. ElewaRM,AbdallahM,Youssef N, Zouboulis CC. Agingrelated changes in cutaneous corticotropin-releasing hormone system reflect a defective neuroendocrine-stress response in aging. Rejuvenation Res. 2012;15:366-373.
246. Alysandratos KD, Asadi S, Angelidou A, et al. Neurotensin and CRH interactions augment human mast cell activation. PLoS One. 2012;7:e48934.
247. Pisarchik A, Wortsman J, Slominski A. Anovel microarray to evaluate stress-related genes in skin: effect of ultraviolet light radiation. Gene. 2004;341:199-207.
248. Ermak G, Slominski A. Production of POMC, CRH-R1, MC1, and MC2 receptor mRNA and expression of tyrosinase gene in relation to hair cycle and dexamethasone treatment in the C57BL/6 mouse skin. J Invest Dermatol. 1997;108:160-165.
249. Zbytek B, Slominski AT. Corticotropin-releasing hormone induces keratinocyte differentiation in the adult human epidermis. J Cell Physiol. 2005;203:118-126.
250. Fazal N, Slominski A, Choudhry MA, Wei ET, Sayeed MM. Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells. FEBS Lett. 1998;435:187-190.
251. Wiesner B, Roloff B, Fechner K, Slominski A. Intracellular calcium measurements of single human skin cells after stimulation with corticotropin-releasing factor and urocortin using confocal laser scanning microscopy. J Cell Sci. 2003;116:1261-1268.
252. Pisarchik A, Slominski A. Molecular and functional characterization of novel CRFR1 isoforms from the skin. Eur J Biochem. 2004;271:2821-2830.
253. Mitsuma T, Matsumoto Y, Tomita Y. Corticotropin releasing hormone stimulates proliferation of keratinocytes. Life Sci. 2001;69:1991-1998.
254. Zbytek B, Pfeffer LM, Slominski AT. Corticotropinreleasing hormone inhibits nuclear factor-_B pathway in human HaCaT keratinocytes. J Invest Dermatol. 2003; 121:1496-1499.
255. Zbytek B, Pfeffer LM, Slominski AT. Corticotropin releasing hormone stimulates NF-κ B in human epidermal keratinocytes. J Endocrinol. 2004;181:R1-R7.
256. Zbytek B, Pikula M, Slominski RM, et al. Corticotropinreleasing hormone triggers differentiation in HaCaT keratinocytes. Br J Dermatol. 2005;152:474-480.
257. Zbytek B, Pfeffer LM, Slominski AT. CRHinhibits NF-κ B signaling inhumanmelanocytes. Peptides. 2006;27:3276-3283.
258. Wei E, Slominski A, inventors; The Regents of the University Of California, Loyola University of Chicago, assignees. Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs. US patent 6803359 B2. October 12, 2004.
259. ZhouCL,YuXJ, ChenLM,Jiang H, Li CY. Corticotropinreleasing hormone attenuates vascular endothelial growth factor release from human HaCaT keratinocytes. Regul Pept. 2010;160:115-120.
260. Park HJ, Kim HJ, Lee JH, et al. Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. J Invest Dermatol. 2005;124:751-755.
261. Zbytek B, Mysliwski A, Slominski A,WortsmanJ,WeiET, Mysliwska J. Corticotropin-releasing hormone affects cytokine production in human HaCaT keratinocytes. Life Sci. 2002;70:1013-1021.
262. Zhao J, Karalis KP. Regulation of nuclear factor-κ B by corticotropin-releasing hormone in mouse thymocytes. Mol Endocrinol. 2002;16:2561-2570.
263. Ross PC, Kostas CM, Ramabhadran TV. A variant of the human corticotropin-releasing factor (CRF) receptor: cloning, expression and pharmacology. Biochem Biophys Res Commun. 1994;205:1836-1842.
264. Zmijewski MA, Slominski AT. Modulation of corticotropin releasing factor (CRF) signaling through receptor splicing in mouse pituitary cell line AtT-20-emerging role of soluble isoforms. J Physiol Pharmacol. 2009;60(suppl 4): 39-46.
265. Teli T, Markovic D, Hewitt ME, Levine MA, Hillhouse EW, Grammatopoulos DK. Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1β and response to PKC phosphorylation. Cell Signal. 2008;20:40-49.
266. Yan G, Zhang G, Fang X, et al. Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol. 2011;29:1019-1023.
267. Kishore S, Khanna A, Zhang Z, et al. The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum Mol Genet. 2010; 19:1153-1164.
268. Liu Z, Zhu F, Wang G, et al. Association of corticotropinreleasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett. 2006;404:358-362.
269. Papiol S, Arias B, GastóC, Gutiérrez B, Catalán R, Fañanás L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104:83-90.
270. Binder EB, Bradley RG, LiuW,et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA. 2008; 299:1291-1305.
271. Bradley RG, Binder EB, Epstein MP, et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry. 2008;65:190-200.
272. Ishitobi Y, Nakayama S, Yamaguchi K, et al. Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2012;159B:429-436.
273. Blomeyer D, Treutlein J, Esser G, SchmidtMH,Schumann G, LauchtM. Interaction betweenCRHR1gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry. 2008;63:146-151.
274. Schmid B, Blomeyer D, Treutlein J, et al. Interacting effects of CRHR1 gene and stressful life events on drinking initiation and progression among 19-year-olds. Int J Neuropsychopharmacol. 2010;13:703-714.
275. Skipper L, Wilkes K, Toft M, et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet. 2004;75:669-677.
276. Licinio J, O'Kirwan F, Irizarry K, et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry. 2004;9:1075-1082.
277. Liu Z, Zhu F, Wang G, et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett. 2007;414:155-158.
278. Kamdem LK, Hamilton L, Cheng C, et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2008;18:507-514.
279. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr Opin Pulm Med. 2009;15:57-62.
280. Jones TS, Kaste SC, Liu W, et al. CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. J Clin Oncol. 2008;26:3031-3037.
281. ElSharawy A, Manaster C, Teuber M, et al. SNPSplicer: systematic analysis of SNP-dependent splicing in genotyped cDNAs. Hum Mutat. 2006;27:1129-1134.
282. Hull J, Campino S, Rowlands K, et al. Identification of commongenetic variation that modulates alternative splicing. PLoS Genet. 2007;3:e99.
283. ElSharawy A, Hundrieser B, Brosch M, et al. Systematic evaluation of the effect of common SNPs on pre-mRNA splicing. Hum Mutat. 2009;30:625-632.
284. Amrani N, Sachs MS, Jacobson A. Early nonsense:mRNA decay solves a translational problem. Nat Rev Mol Cell Biol. 2006;7:415-425.
285. WangGS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007;8:749-761.
286. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13: 1353-1359.
287. Keck ME, Kern N, Erhardt A, et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1196-1204.
288. Tantisira KG, Lazarus R, Litonjua AA, Klanderman B, Weiss ST.Chromosome17: association of a large inversion polymorphism with corticosteroid response in asthma. Pharmacogenet Genomics. 2008;18:733-737.
289. Wasserman D, Sokolowski M, Rozanov V, Wasserman J. The CRHR1 gene: a marker for suicidality in depressed males exposed to low stress. Genes Brain Behav. 2008;7: 14-19.
290. Cruchaga C, Vidal-Taboada JM, Ezquerra M, et al. 5'-Upstream variants ofCRHR1andMAPTgenes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiol Dis. 2009;33:164-170.
291. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM,Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry. 2009;66:681-685.
292. Wasserman D, Wasserman J, Rozanov V, Sokolowski M. Depression in suicidal males: genetic risk variants in the CRHR1 gene. Genes Brain Behav. 2009;8:72-79.
293. Schmidt ED, Aguilera G, Binnekade R, Tilders FJ. Single administration of interleukin-1 increased corticotropin releasing hormone and corticotropin releasing hormone receptormRNAin the hypothalamic paraventricular nucleus which paralleled long-lasting (weeks) sensitization to emotional stressors. Neuroscience. 2003;116:275-283.
294. Markovic D, Vatish M, Gu M, et al. The onset of labor alters corticotropin-releasing hormone type 1 receptor variant expression in human myometrium: putative role of interleukin-1β. Endocrinology. 2007;148:3205-3213.
295. Coste SC, Heldwein KA, Stevens SL, Tobar-Dupres E, Stenzel-Poore MP. IL-1α and TNFα down-regulate CRH receptor-2 mRNA expression in the mouse heart. Endocrinology. 2001;142:3537-3545.
296. Aubry JM, Turnbull AV, Pozzoli G, Rivier C, Vale W. Endotoxin decreases corticotropin-releasing factor receptor 1 messenger ribonucleic acid levels in the rat pituitary. Endocrinology. 1997;138:1621-1626.
297. Parsadaniantz SM, Batsche E, Gegout-Pottie P, et al. Effects of continuous infusion of interleukin 1 β on corticotropin-releasing hormone (CRH), CRH receptors, proopiomelanocortin gene expression and secretion of corticotropin, β-endorphin and corticosterone. Neuroendocrinology. 1997;65:53-63.
298. O'ConnorTM,O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167-180.
299. Peters EM, Arck PC, Paus R. Hair growth inhibition by psychoemotional stress: a mouse model for neural mechanisms in hair growth control. Exp Dermatol. 2006;15: 1-13.
300. Hamke M, Herpfer I, Lieb K, Wandelt C, Fiebich BL. Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor. Brain Res. 2006;1102:135-144.
301. Papadopoulou NG, Oleson L, Kempuraj D, Donelan J, Cetrulo CL, Theoharides TC. Regulation of corticotropinreleasing hormone receptor-2 expression in human cord blood-derived cultured mast cells. J Mol Endocrinol. 2005; 35:R1-R8.
302. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol. 2006; 126:1705-1718.
303. Reich A, Wojcik-Maciejewicz A, Slominski AT. Stress and the skin. G Ital Dermatol Venereol. 2010;145:213-219.
304. Slominski A. A nervous breakdown in the skin: stress and the epidermal barrier. J Clin Invest. 2007;117:3166-3169.
305. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev. 2007; 217:65-78.
306. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10:440-452.
307. Chakraborty AK, Funasaka Y, Slominski A, et al. UV light and MSH receptors. Ann NY Acad Sci. 1999;885:100-116.
308. Bolognia J, Murray M, Pawelek J. UVB-induced melanogenesis may be mediated through the MSH-receptor system. J Invest Dermatol. 1989;92:651-656.
309. Pawelek JM, Chakraborty AK, Osber MP, et al. Molecular cascades in UV-induced melanogenesis: a central role for melanotropins? Pigment Cell Res. 1992;5:348-356.
310. Chakraborty A, Slominski A, Ermak G, Hwang J, Pawelek J. Ultraviolet B and melanocyte-stimulating hormone (MSH) stimulate mRNA production for α MSH receptors and proopiomelanocortin-derived peptides in mouse melanoma cells and transformed keratinocytes. J Invest Dermatol. 1995;105:655-659.
311. Chakraborty AK, Funasaka Y, Slominski A, et al. Production and release of proopiomelanocortin (POMC) derived peptides by human melanocytes and keratinocytes in culture: regulation by ultraviolet B. Biochim Biophys Acta. 1996;1313:130-138.
312. Slominski A, Pawelek J. Animals under the sun: effects of ultraviolet radiation on mammalian skin. Clin Dermatol. 1998;16:503-515.
313. Pawelek J, Bolognia J, McLane J, Murray M, Osber M, Slominski A. A possible role for melanin precursors in regulating both pigmentation and proliferation of melanocytes. Prog Clin Biol Res. 1988;256:143-154.
314. Gilchrest BA, Park HY, Eller MS, Yaar M. Mechanisms of ultraviolet light-induced pigmentation. Photochem Photobiol. 1996;63:1-10.
315. Funasaka Y, Chakraborty AK, Hayashi Y, et al. Modulation of melanocyte-stimulating hormone receptor expression on normal human melanocytes: evidence for a regulatory role of ultraviolet B, interleukin-1α, interleukin-1β, endothelin-1 and tumour necrosis factor-α. Br J Dermatol. 1998;139:216-224.
316. BöhmM, Wolff I, Scholzen TE, et al. α-Melanocyte-stimulating hormone protects from ultraviolet radiationinduced apoptosis and DNA damage. J Biol Chem. 2005; 280:5795-5802.
317. Böhm M, Luger TA, Tobin DJ, Garcia-Borron JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol. 2006;126: 1966-1975.
318. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R. The melanocortin 1 receptor and the UV response of human melanocytes-a shift in paradigm. Photochem Photobiol. 2008;84:501-508.
319. Abdel-Malek ZA, Kadekaro AL, Swope VB. Stepping up melanocytes to the challenge ofUVexposure. Pigment Cell Melanoma Res. 2010;23:171-186.
320. Ito N, Ito T, Kromminga A, et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J. 2005; 19:1332-1334.321.
321. Slominski A, Zbytek B, Semak I, Sweatman T, Wortsman J. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol. 2005; 162:97-102.
322. Slominski A, Zbytek B, Szczesniewski A, et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am J Physiol Endocrinol Metab. 2005; 288:E701-E706.
323. Rousseau K, Kauser S, Pritchard LE, et al. Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis. FASEB J. 2007;21: 1844-1856.
324. Sharpley CF, Kauter KG, McFarlane JR. An initial exploration of in vivo hair cortisol responses to a brief pain stressor: latency, localization and independence effects. Physiol Res. 2009;58:757-761.
325. Sharpley CF, Kauter KG, McFarlane JR. Hair cortisol concentration differs across site and person: localization and consistency of responses to a brief pain stressor. Physiol Res. 2010;59:979-983.
326. Sharpley CF, Kauter KG, McFarlane JR. An investigation of hair cortisol concentration across body sites and within hair shaft. Clin Med Insights Endocrinol Diabetes. 2010; 3:17-23.
327. Kimura A, Kanazawa N, Li HJ, Yonei N, Yamamoto Y, Furukawa F. Influence of chemical peeling on the skin stress response system. Exp Dermatol. 2012;21(suppl 1): 8-10.
328. Arck P, Handjiski B, Hagen E, et al. Is there a 'gut-brainskin axis'? Exp Dermatol. 2010;19:401-405.
329. Alexacos N, Pang X, Boucher W, Cochrane DE, Sant GR, Theoharides TC. Neurotensin mediates rat bladder mast cell degranulation triggered by acute psychological stress. Urology. 1999;53:1035-1040.
330. BoucherW,Kempuraj D, MichaelianM,Theoharides TC. Corticotropin-releasing hormone-receptor 2 is required for acute stress-induced bladder vascular permeability and release of vascular endothelial growth factor. BJU Int. 2010;106:1394-1399.
331. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med. 2011;62:381-396.
332. Bonaz BL, Bernstein CN. 2012 Brain-gut interactions in inflammatory bowel diseases. Gastroenterology. 2013; 144:36-49.
333. TachéY, Perdue MH. Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil. 2004; 16(suppl 1):137-142.
334. Stengel A, TachéY. Corticotropin-releasing factor signaling and visceral response to stress. Exp Biol Med (Maywood). 2010;235:1168-1178.
335. Kresse AE, Million M, Saperas E, TachéY. Colitis induces CRF expression in hypothalamic magnocellular neurons and bluntsCRFgene response to stress in rats.AmJ Physiol Gastrointest Liver Physiol. 2001;281:G1203-G1213.
336. Wlk M, Wang CC, Venihaki M, et al. Corticotropinreleasing hormone antagonists possess anti-inflammatory effects in the mouse ileum. Gastroenterology. 2002;123: 505-515.
337. Santos J, Saunders PR, Hanssen NP, et al. Corticotropinreleasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. Am J Physiol. 1999;277: G391-G399.
338. Eutamene H, Theodorou V, Fioramonti J, Bueno L. Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats. J Physiol. 2003;553: 959-966.
339. Im E, Rhee SH, Park YS, Fiocchi C, TachéY, Pothoulakis C. Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis. Gastroenterology. 2010; 138:2457-2467.e1-e5.
340. Jones HP. Immune cells listen to what stress is saying: neuroendocrine receptors orchestrate immune function. Methods Mol Biol. 2012;934:77-87.
341. Theoharides TC, Enakuaa S, Sismanopoulos N, et al. Contribution of stress to asthma worsening through mast cell activation. Ann Allergy Asthma Immunol. 2012;109:14-19.
342. Dhabhar FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation. 2009; 16:300-317.
343. Katsarou-Katsari A, Filippou A, Theoharides TC. Effect of stress and other psychological factors on the pathophysiology and treatment of dermatoses. Int J Immunopathol Pharmacol. 1999;12:7-11.
344. Tsagarakis S, Grossman A. Corticotropin-releasing hormone: interactions with the immune system. Neuroimmunomodulation. 1994;1:329-334.
345. Kalantaridou S, Makrigiannakis A, Zoumakis E, Chrousos GP. Peripheral corticotropin-releasing hormone is produced in the immune and reproductive systems: actions, potential roles and clinical implications. Front Biosci. 2007;12:572-580.
346. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563-568.
347. Baigent SM. Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response. Peptides. 2001;22:809-820.
348. Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology. 1998;139:403-413.
349. Singh LK, Boucher W, Pang X, et al. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J Pharmacol Exp Ther. 1999;288:1349-1356.
350. Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822:21-33.
351. Wolfe CD, Patel SP, Linton EA, et al. Plasma corticotrophin-releasing factor (CRF) in abnormal pregnancy. Br J Obstet Gynaecol. 1988;95:1003-1006.
352. Jeske W, Soszynski P, Lukaszewicz E, et al. Enhancement of plasma corticotropin-releasing hormone in pregnancy-induced hypertension. Acta Endocrinol (Copenh). 1990; 122:711-714.
353. Warren WB, Patrick SL, Goland RS. Elevated maternal plasma corticotropin-releasing hormone levels in pregnancies complicated by preterm labor. Am J Obstet Gynecol. 1992;166:1198-1204; discussion 1204-1207.
354. McLean M, Bisits A, Davies J, Woods R, Lowry P, Smith R. A placental clock controlling the length of human pregnancy. Nat Med. 1995;1:460-463.
355. LeungTN,ChungTK,MadsenG,McLeanM,ChangAM, Smith R. Elevated mid-trimester maternal corticotrophinreleasing hormone levels in pregnancies that delivered before 34 weeks. Br J Obstet Gynaecol. 1999;106:1041-1046.
356. Vrachnis N, Malamas FM, Sifakis S, Tsikouras P, Iliodromiti Z. Immune aspects and myometrial actions of progesterone and CRH in labor. Clin Dev Immunol. 2012; 2012:937618.
357. Kempuraj D, Papadopoulou N, Stanford EJ, et al. Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. Am J Reprod Immunol. 2004;52:267-275.
358. Tariverdian N, Theoharides TC, Siedentopf F, et al. Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol. 2007;29:193-210.
359. Overton JM, Fisher LA. Modulation of central nervous system actions of corticotropin-releasing factor by dynorphin-related peptides. Brain Res. 1989;488:233-240.
360. Weisinger RS, Blair-West JR, Burns P, et al. Cardiovascular effects of long-term central and peripheral administration of urocortin, corticotropin-releasing factor, and adrenocorticotropin in sheep. Endocrinology. 2004;145: 5598-5604.
361. Abdelrahman AM, Lin Lim S, Pang CC. Influence of urocortin and corticotropin releasing factor on venous tone in conscious rats. Eur J Pharmacol. 2005;510:107-111.
362. Grossini E, Molinari C, Mary DA, Marino P, Vacca G. The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric-oxide-dependent. Eur J Pharmacol. 2008;578:242-248.
363. Grossini E, Molinari C, Mary DA, et al. Urocortin II induces nitric oxide production through cAMP and Ca2_ related pathways in endothelial cells. Cell Physiol Biochem. 2009;23:87-96.
364. Overton JM, Fisher LA. Differentiated hemodynamic responses to central versus peripheral administration of corticotropin-releasing factor in conscious rats. J Auton Nerv Syst. 1991;35:43-51.
365. Davis ME, Pemberton CJ, Yandle TG, et al. Urocortin 2 infusion in human heart failure. Eur Heart J. 2007;28: 2589-2597.
366. Yang LZ, Kockskamper J, Heinzel FR, et al. Urocortin II enhances contractility in rabbit ventricular myocytes via CRF(2) receptor-mediated stimulation of protein kinase A. Cardiovasc Res. 2006;69:402-411.
367. Calderon-Sanchez E, Delgado C, Ruiz-Hurtado G, et al. Urocortin induces positive inotropic effect in rat heart. Cardiovasc Res. 2009;83:717-725.
368. Huang M, Pang X, Letourneau R, Boucher W, Theoharides TC. Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in apolipoprotein E knockout mice. Cardiovasc Res. 2002; 55:150-160.
369. Huang M, Pang X, Karalis K, Theoharides TC. Stressinduced interleukin-6 release in mice is mast cell-dependent and more pronounced in apolipoprotein E knockout mice. Cardiovasc Res. 2003;59:241-249.
370. kB activation. J Mol Endocrinol. 2009;42:397-405.
371. Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS, Tate DA, Dehmer GJ. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure.AmJ Cardiol. 2000;86:913-918.
372. Theoharides TC, Sismanopoulos N, Delivanis DA, Zhang B, Hatziagelaki EE, Kalogeromitros D. Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. Trends Pharmacol Sci. 2011;32:534-542.
373. Slominski A, Paus R, Mazurkiewicz J. Proopiomelanocortin expression in the skin during induced hair growth in mice. Experientia. 1992;48:50-54.
374. Paus R. A neuroendocrinological perspective on human hair follicle pigmentation. Pigment Cell Melanoma Res. 2011;24:89-106.
375. Slominski A, Paus R, Wortsman J. On the potential role of proopiomelanocortin in skin physiology and pathology. Mol Cell Endocrinol. 1993;93:C1-C6.
376. Slominski A, Wortsman J, Mazurkiewicz JE, et al. Detection of proopiomelanocortin-derived antigens in normal and pathologic human skin. J Lab Clin Med. 1993;122: 658-666.
377. Wintzen M, Gilchrest BA. Proopiomelanocortin, its derived peptides, and the skin. J Invest Dermatol. 1996;106: 3-10.
378. Nagahama M, Funasaka Y, Fernandez-Frez ML, et al. Immunoreactivity of α-melanocyte-stimulating hormone, adrenocorticotrophic hormone and β-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br J Dermatol. 1998;138:981-985.
379. Slominski A. Identification of β-endorphin, α -MSH and ACTH peptides in cultured human melanocytes, melanoma and squamous cell carcinoma cells by RP-HPLC. Exp Dermatol. 1998;7:213-216.
380. Luger T, Paus R, Lipton J, Slominski A. Cutaneous Neuromodulation: the Proopiomelanocortin System. Ann NY Acad Sci. 1999;885:1-479.
381. Slominski A, Heasley D, Mazurkiewicz JE, Ermak G, Baker J, Carlson JA. Expression of proopiomelanocortin (POMC)-derived melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) peptides in skin of basal cell carcinoma patients. Hum Pathol. 1999;30:208-215.
382. Mazurkiewicz JE, Corliss D, Slominski A. Spatiotemporal expression, distribution, and processing of POMC and POMC-derived peptides in murine skin. J Histochem Cytochem. 2000;48:905-914.
383. Peters EM, Tobin DJ, Seidah NG, Schallreuter KU. Proopiomelanocortin-related peptides, prohormone convertases 1 and 2 and the regulatory peptide 7B2 are present in melanosomes of human melanocytes. J Invest Dermatol. 2000;114:430-437.
384. Pritchard LE, White A. Neuropeptide processing and its impact on melanocortin pathways. Endocrinology. 2007; 148:4201-4207.
385. Kauser S, Thody AJ, Schallreuter KU, Gummer CL, Tobin DJ. β-Endorphin as a regulator of human hair follicle melanocyte biology. J Invest Dermatol. 2004;123:184-195.
386. Tobin DJ, Kauser S. Hair melanocytes as neuro-endocrine sensors-pigments for our imagination. Mol Cell Endocrinol. 2005;243:1-11.
387. Tobin DJ, Kauser S. β-Endorphin: the forgotten hair follicle melanotropin. J Investig Dermatol Symp Proc. 2005; 10:212-216.
388. Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126:1697-1704.
389. Zeller S, Lazovich D, Forster J, Widome R. Do adolescent indoor tanners exhibit dependency? J AmAcad Dermatol. 2006;54:589-596.
390. Slominski A, Ermak G, Mihm M. ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. J Clin Endocrinol Metab. 1996;81:2746-2749.
391. Slominski A, Gomez-Sanchez CE, Foecking MF, Wortsman J. Metabolism of progesterone to DOC, corticosterone and 18OHDOC in cultured human melanoma cells. FEBS Lett. 1999;455:364-366.
392. Slominski A, Gomez-Sanchez C, Foecking MF, Wortsman J. Active steroidogenesis in the normal rat skin. Biochim Biophys Acta. 2000;1474:1-4.
393. Rogoff D, Gomez-Sanchez CE, Foecking MF, Wortsman J, Slominski A. Steroidogenesis in the human skin: 21-hydroxylation in cultured keratinocytes. J Steroid Biochem Mol Biol. 2001;78:77-81.
394. Milewich L, Shaw CB, Sontheimer RD. Steroid metabolism by epidermal keratinocytes. Ann NY Acad Sci. 1988; 548:66-89.
395. Labrie F, Luu-The V, Labrie C, Pelletier G, El-Alfy M. Intracrinology and the skin. Horm Res. 2000;54:218-229.
396. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003;24: 152-182.
397. Slominski A, Zbytek B, Szczesniewski A, Wortsman J. Cultured human dermal fibroblasts do produce cortisol. J Invest Dermatol. 2006;126:1177-1178.
398. Cirillo N, Prime SS. Keratinocytes synthesize and activate cortisol. J Cell Biochem. 2011;112:1499-1505.
399. Hannen RF, Michael AE, Jaulim A, Bhogal R, Burrin JM, Philpott MP. Steroid synthesis by primary human keratinocytes; implications for skin disease. Biochem Biophys Res Commun. 2011;404:62-67.
400. Vukelic S, Stojadinovic O, Pastar I, et al. Cortisol synthesis in epidermis is induced by IL-1 and tissue injury. J Biol Chem. 2011;286:10265-10275.
401. Skobowiat C, Sayre RM, Dowdy JC, Slominski AT. Ultraviolet radiation regulates cortisol activity in a waveband-dependent manner in human skin ex vivo. Br J Dermatol. 2013;168:595-601.
402. Tiganescu A, Walker EA, Hardy RS, Mayes AE, Stewart PM. Localization, age- and site-dependent expression, and regulation of 11β-hydroxysteroid dehydrogenase type 1 in skin. J Invest Dermatol. 2011;131:30-36.
403. Zouboulis CC, Degitz K. Androgen action on human skin-from basic research to clinical significance. Exp Dermatol. 2004;13(suppl 4):5-10.
404. Milewich L, Shaw CE, Doody KM, Rainey WE, Mason JI, Carr BR. 3β-Hydroxysteroid dehydrogenase activity in glandular and extraglandular human fetal tissues. J Clin Endocrinol Metab. 1991;73:1134-1140.
405. Simard J, Couet J, Durocher F, et al. Structure and tissuespecific expression of a novel member of the rat 3 β-hydroxysteroid dehydrogenase/{rectangle open5-{rectangle open4 isomerase (3β-HSD) family. The exclusive 3β-HSD gene expression in the skin. J Biol Chem. 1993;268:19659-19668.
406. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004;22:360-366.
407. Zmijewski MA, Li W, Zjawiony JK, et al. Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci. 2008;7:1570-1576.
408. Zmijewski MA, Li W, Chen J, et al. Synthesis and photochemical transformation of 3β,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity. Steroids. 2011;76:193-203.
409. Slominski AT, Kim TK, Janjetovic Z, et al. 20-Hydroxyvitamin D2 is a noncalcemic analog of vitaminDwith potent antiproliferative and prodifferentiation activities in normal and malignant cells. Am J Physiol Cell Physiol. 2011; 300:C526-C541.
410. Slominski AT, Li W, Bhattacharya SK, et al. Vitamin D analogs 17,20S(OH)2pD and 17,20R(OH)2pD are noncalcemic and exhibit antifibrotic activity. J Invest Dermatol. 2011;131:1167-1169.
411. Slominski AT, Janjetovic Z, Fuller BE, et al. Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity. PLoS One. 2010;5:e9907.
412. kB activity in human keratinocytes. J Cell Physiol. 2010;223:36-48.
413. Zbytek B, Janjetovic Z, Tuckey RC, et al. 20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol. 2008;128:2271-2280.
414. kB α levels in human keratinocytes. PLoS One. 2009;4: e5988.
415. Wang J, Slominski A, Tuckey RC, et al. 20-Hydroxyvitamin D(3) inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res. 2012;32: 739-746.
416. Slominski AT, Janjetovic Z, Kim TK, et al. Novel vitamin D hydroxyderivatives inhibit melanoma growth and showdifferential effects on normal melanocytes. Anticancer Res. 2012;32:3733-3742.
417. kB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. Br J Cancer. 2011;105:1874-1884.
418. Slominski A, Janjetovic Z, Tuckey RC, et al. 20S-Hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab. 2013;98:E298-E303.
419. Slominski A. POMC gene expression in mouse and hamster melanoma cells. FEBS Lett. 1991;291:165-168.
420. Schauer E, Trautinger F, Kock A, et al. Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest. 1994;93:2258-2262.
421. Dumont M, Luu-The V, Dupont E, Pelletier G, Labrie F. Characterization, expression, and immunohistochemical localization of 3 β-hydroxysteroid dehydrogenase/{rectangle open5-{rectangle open4 isomerase in human skin. J Invest Dermatol. 1992;99: 415-421.
422. Moustafa M, Szabo M, Ghanem GE, et al. Inhibition of tumor necrosis factor-α stimulated NFκB/p65 in human keratinocytes by α-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. J Invest Dermatol. 2002;119:1244-1253.
423. Park HJ, Kim HJ, Lee JY, Cho BK, Gallo RL, Cho DH. Adrenocorticotropin hormone stimulates interleukin-18 expression in human HaCaT keratinocytes. J Invest Dermatol. 2007;127:1210-1216.
424. Sato H, Nagashima Y, Chrousos GP, IchihashiM,Funasak Y. The expression of corticotropin-releasing hormone in melanoma. Pigment Cell Res. 2002;15:98-103.
425. Sharpley CF, McFarlane JR, Slominski A. Stress-linked cortisol concentrations in hair: whatweknowand whatwe need to know. Rev Neurosci. 2011;23:111-121.
426. Crofford LJ, Sano H, Karalis K, et al. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol. 1993;151:1587-1596.
427. Malysheva O, Wagner U, Wahle M, Wagner U, Stalla GK, Baerwald CG. Corticotropin releasing hormone (CRH) response in patients with early rheumatoid arthritis due to polymorphisms in the CRH gene. Clin Exp Rheumatol. 2012;30:421-423.
428. Oh SH, Park CO, Wu WH, et al. Corticotropin-releasing hormone downregulates IL-10 production by adaptive forkhead box protein 3-negative regulatory T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2012;129:151-159.e1-e6.
429. Blalock JE. A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev. 1989;69:1-32.
430. Blalock JE. The syntax of immune-neuroendocrine communication. Immunol Today. 1994;15:504-511.
431. Tatro JB. Receptor biology of the melanocortins, a family of neuroimmunomodulatory peptides. Neuroimmunomodulation. 1996;3:259-284.
432. Brzoska T, Luger TA, Maaser C, Abels C, BöhmM.α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29:581-602.
433. Mountjoy KG. Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. Biochem J. 2010; 428:305-324.
434. BöhmM, Grässel S. Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research. Endocr Rev. 2012; 33:623-651.
435. Tzioufas AG, Tsonis J, Moutsopoulos HM. Neuroendocrine dysfunction in Sjogren's syndrome. Neuroimmunomodulation. 2008;15:37-45.
436. Wei ET, Gao GC, Thomas HA. Peripheral anti-inflammatory actions of corticotropin-releasing factor. Ciba Found Symp. 1993;172:258-268; discussion 268-276.
437. Inada Y, Ikeda K, Tojo K, SakamotoM,Takada Y, Tajima N. Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation. Peptides. 2009;30:365-372.
438. Zhu H, Wang J, Li J, Li S. Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery? Inflamm Res. 2011;60: 715-721.
439. Kaprara A, Pazaitou-Panayiotou K, Kortsaris A, Chatzaki E. The corticotropin releasing factor system in cancer: expression and pathophysiological implications. Cell Mol Life Sci. 2010;67:1293-1306.
440. Vacchio MS, Papadopoulos V, Ashwell JD. Steroid production in the thymus: implications for thymocyte selection. J Exp Med. 1994;179:1835-1846.
441. Iscan M, Klaavuniemi T, Coban T, Kapucuoglu N, Pelkonen O, Raunio H. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat. 2001;70:47-54.
442. Locke JA, Fazli L,AdomatH, et al.Anovel communication role for CYP17A1 in the progression of castration-resistant prostate cancer. Prostate. 2009;69:928-937.
443. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011;18:R175-R182.
444. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71:6503-6513.
445. Fernandez-Marcos PJ, Auwerx J, Schoonjans K. Emerging actions of the nuclear receptor LRH-1 in the gut. Biochim Biophys Acta. 2011;1812:947-955.
446. Sidler D, Renzulli P, Schnoz C, et al. Colon cancer cells produce immunoregulatory glucocorticoids. Oncogene. 2011;30:2411-2419.
447. Bennett NC, Hooper JD, Lambie D, et al. Evidence for steroidogenic potential in human prostate cell lines and tissues. Am J Pathol. 2012;181:1078-1087.
448. Courtney KD, Taplin ME. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Curr Opin Oncol. 2012;24:272-277.
449. Levina E, Chen M, Carkner R, Shtutman M, Buttyan R. Paracrine Hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli-dependent manner. Prostate. 2012;72:817-824.
450. Mostaghel EA, Solomon KR, Pelton K, Freeman MR,Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One. 2012;7:e30062.
451. Watzka M, Bidlingmaier F, Schramm J, Klingmuller D, Stoffel-Wagner B. Sex- and age-specific differences in human brain CYP11A1 mRNA expression. J Neuroendocrinol. 1999;11:901-905.
452. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81-151.
453. Noti M, Corazza N, Tuffin G, Schoonjans K, Brunner T. Lipopolysaccharide induces intestinal glucocorticoid synthesis in a TNFα-dependent manner. FASEB J. 2010;24: 1340-1346.
454. Slominski A. Neuroendocrine system of the skin. Dermatology. 2005;211:199-208.
455. Holtzmann H, Altmeyer P, Schultz-AmlingW.Der einfluss ultravioletter strtahlen auf die hypothalamus-hypophysenachse des menschen. Acta Dermatol. 1982;8:119-123.
456. Holtzmann H, Altmeyer P, Stohr L, Chilf GN. Die beemfussung des α-MSH durch UVA-bestrahlunger der hautein funktionstest. Hautarzt. 1983;34:294-297.
457. Levins PC, Carr DB, Fisher JE, Momtaz K, Parrish JA. Plasma β-endorphin and β-lipoprotein response to ultraviolet radiation. Lancet. 1983;2:166.
458. Belon PE. UVA exposure and pituitary secretion. Variations of human lipotropin concentrations (β LPH) after UVA exposure. Photochem Photobiol. 1985;42:327-329.
459. Paz ML, Ferrari A, Weill FS, Leoni J, Maglio DH. Timecourse evaluation and treatment of skin inflammatory immune response after ultraviolet B irradiation. Cytokine. 2008;44:70-77.
460. Bernard JJ, Cowing-Zitron C, Nakatsuji T, et al. 2012 Ultraviolet radiation damages self noncoding RNA and is detected by TLR3 [published online ahead of print July 8, 2012]. Nat Med. doi:10.1038/nm.2861.
461. Urbanski A, Schwarz T, Neuner P, et al. Ultraviolet light induces increased circulating interleukin-6 in humans. J Invest Dermatol. 1990;94:808-811.
462. Kripke ML. Ultraviolet radiation and immunology: something new under the sun-presidential address. Cancer Res. 1994;54:6102-6105.
463. Beissert S, Schwarz T. Mechanisms involved in ultraviolet light-induced immunosuppression. J Investig Dermatol Symp Proc. 1999;4:61-64.
464. Bornstein SR, Rutkowski H, Vrezas I. Cytokines and steroidogenesis. Mol Cell Endocrinol. 2004;215:135-141.
465. Bornstein SR, Zacharowski P, Schumann RR, et al. Impaired adrenal stress response in Toll-like receptor 2-deficient mice. Proc Natl Acad Sci USA. 2004;101:16695-16700.
466. Zacharowski K, Zacharowski PA, Koch A, et al. Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci USA. 2006;103:6392-6397.
467. Tran N, Koch A, Berkels R, et al. Toll-like receptor 9 expression in murine and human adrenal glands and possible implications during inflammation. J Clin Endocrinol Metab. 2007;92:2773-2783.
468. Kanczkowski W, Zacharowski K, Wirth MP, Ehrhart-Bornstein M, Bornstein SR. Differential expression and action of Toll-like receptors in human adrenocortical cells. Mol Cell Endocrinol. 2009;300:57-65.
469. Kanczkowski W, Zacharowski K, Bornstein SR. Role of toll-like receptors and inflammation in adrenal gland insufficiency. Neuroimmunomodulation. 2010;17:180-183.
470. Manna PR, Chandrala SP, Jo Y, Stocco DM. cAMP-independent signaling regulates steroidogenesis in mouse Leydig cells in the absence of StAR phosphorylation. J Mol Endocrinol. 2006;37:81-95.
471. Deak T. Immune cells and cytokine circuits: toward a working model for understanding direct immune-to-adrenal communication pathways. Endocrinology. 2008;149: 1433-1435.
472. Engstrom L, Rosen K, Angel A, et al. Systemic immune challenge activates an intrinsically regulated local inflammatory circuit in the adrenal gland. Endocrinology. 2008; 149:1436-1450.
473. Mikhaylova IV, Jäskeläinen T, Jää skeläinen J, Palvimo JJ, Voutilainen R. Leukemia inhibitory factor as a regulator of steroidogenesis in human NCI-H295R adrenocortical cells. J Endocrinol. 2008;199:435-444.
474. Martinez Calejman C, Astort F, Di Gruccio JM, et al. Lipopolysaccharide stimulates adrenal steroidogenesis in rodent cells by a NFκB-dependent mechanism involving COX-2 activation. Mol Cell Endocrinol. 2011;337:1-6.
475. Tkachenko IV, Jaaskelainen T, Jaaskelainen J, Palvimo JJ, Voutilainen R. Interleukins 1α and 1β as regulators of steroidogenesis in human NCI-H295R adrenocortical cells. Steroids. 2011;76:1103-1115.
476. Becklund BR, Severson KS, Vang SV, DeLuca HF. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci USA. 2010;107:6418-6423.
477. Nolan BV, Taylor SL, Liguori A, Feldman SR. Tanning as an addictive behavior: a literature review. Photodermatol Photoimmunol Photomed. 2009;25:12-19.
478. Kourosh AS, Harrington CR, Adinoff B. Tanning as a behavioral addiction. Am J Drug Alcohol Abuse. 2010;36: 284-290.
479. Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene. 2001;20:2413-2423.
480. Moroz MA, Huang R, Kochetkov T, et al. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clin Cancer Res. 2011;17:3282-3292.
481. Graziani G, Tentori L, Muzi A, et al. Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol. 2007;264:44-49.
482. Graziani G, Tentori L, Portarena I, et al. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology. 2002;143:807-813.
483. Carlson KW, Nawy SS, Wei ET, et al. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res. 2001;21:1173-1179.
484. Choi EH, Demerjian M, Crumrine D, et al. Glucocorticoidblockade reverses psychological stress-induced abnormalities in epidermal structure and function. Am J Physiol Regul Integr Comp Physiol. 2006;291:R1657-1662.
485. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73:213-224.
486. Catania A, Colombo G, Rossi C, et al. Antimicrobial properties of α-MSH and related synthetic melanocortins. ScientificWorldJournal. 2006;6:1241-1246.
487. Keita AV, Soderholm JD, Ericson AC. Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells. Neurogastroenterol Motil. 2010;22: 770-778:e221-e222.
488. Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut. 2008;57:50-58.
489. Theoharides TC, Spanos C, Pang X, et al. Stress-induced intracranial mast cell degranulation: a corticotropinreleasing hormone-mediated effect. Endocrinology. 1995; 136:5745-5750.
490. Esposito P, Chandler N, Kandere K, et al. Corticotropinreleasing hormone and brain mast cells regulate bloodbrain-barrier permeability induced by acute stress. J Pharmacol Exp Ther. 2002;303:1061-1066.
491. Theoharides TC, Rozniecki JJ, Sahagian G, et al. Impact of stress and mast cells on brain metastases. J Neuroimmunol. 2008;205:1-7.
492. Tobin DJ. The cell biology of human hair follicle pigmentation. Pigment Cell Melanoma Res. 2011;24:75-88.
493. Kauser S, Thody AJ, Schallreuter KU, Gummer CL, Tobin DJ. A fully functional proopiomelanocortin/melanocortin-1 receptor system regulates the differentiation of human scalp hair follicle melanocytes. Endocrinology. 2005; 146:532-543.
494. Lerner AB, McGuire JS. Effect of α- and βmelanocyte stimulating hormones on the skin colour of man. Nature. 1961; 189:176-179.
495. Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266:2730-2736.
496. Hunt G, Donatien PD, Lunec J, Todd C, Kyne S, Thody AJ. Cultured human melanocytes respond to MSH peptides and ACTH. Pigment Cell Res. 1994;7:217-221.
497. Hunt G, Todd C, Cresswell JE, Thody AJ. α-Melanocyte stimulating hormone and its analogue Nle4DPhe7α-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci. 1994;107:205-211.
498. Hunt G, Todd C, Kyne S, Thody AJ. ACTH stimulates melanogenesis in cultured human melanocytes. J Endocrinol. 1994;140:R1-R3.
499. Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology. 1996;137: 1627-1633.
500. Wakamatsu K, Graham A, Cook D, Thody AJ. Characterisation of ACTH peptides in human skin and their activation of the melanocortin-1 receptor. Pigment Cell Res. 1997;10:288-297.
501. Tsatmalia M, Wakamatsu K, Graham AJ, Thody AJ. Skin POMC peptides. Their binding affinities and activation of the human MC1 receptor. Ann NY Acad Sci. 1999;885: 466-469.
502. Tsatmali M, Ancans J, Thody AJ. Melanocyte function and its control by melanocortin peptides. J Histochem Cytochem. 2002;50:125-133.
503. Kauser S, Westgate GE, GreenMR,Tobin DJ.Humanhair follicle and epidermal melanocytes exhibit striking differences in their aging profile which involves catalase. J Invest Dermatol. 2011;131:979-982.
504. Tobin DJ. Ex vivo organ culture of human hair follicles: a model epithelial-neuroectodermal-mesenchymal interaction system. Methods Mol Biol. 2011;695:213-227.
505. Slominski A, Costantino R, Wortsman J, Paus R, Ling N. Melanotropic activity of γ MSH peptides in melanoma cells. Life Sci. 1992;50:1103-1108.
506. Slominski A, Plonka PM, Pisarchik A, et al. Preservation of eumelanin hair pigmentation in proopiomelanocortindeficient mice on a nonagouti (a/a) genetic background. Endocrinology. 2005;146:1245-1253.
507. Pedersen WA, Wan R, Zhang P, Mattson MP. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J Neurosci. 2002;22:404-412.
508. Kadekaro AL, Kavanagh R, Kanto H, et al. α-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res. 2005;65:4292-4299.
509. Watanuki Y, Takayasu S, Kageyama K, et al. 2013 Involvement of Nurr-1/Nur77 in corticotropin-releasing factor/ urocortin1-induced tyrosinase-related protein 1 gene transcription in human melanoma HMV-II cells. Mol Cell Endocrinol. 2013;370:42-51.
510. Tobin DJ, Bystryn JC. Different populations of melanocytes are present in hair follicles and epidermis. Pigment Cell Res. 1996;9:304-310.
511. Nordlund JJ, Ortonne JP. The normal color of human skin. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP, eds. The Pigmentary System: Physiology and Pathophysiology. Oxford, UK: Oxford University Press; 1998: 475-587.
512. Slominski A, Paus R. Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J Invest Dermatol. 1993;101(1 suppl):90S-97S.
513. Shafton AD, Oldfield BJ, McAllen RM. CRF-like immunoreactivity selectively labels preganglionic sudomotor neurons in cat. Brain Res. 1992;599:253-260.
514. Janson DG, Saintigny G, van Adrichem A, Mahe C, El Ghalbzouri A. Different gene expression patterns in human papillary and reticular fibroblasts. J Invest Dermatol. 2012;132:2565-2572.
515. Tobin DJ, Gunin A, Magerl M, Handijski B, Paus R. Plasticity and cytokinetic dynamics of the hair follicle mesenchyme: implications for hair growth control. J Invest Dermatol. 2003;120:895-904.
516. Collins CA, Jensen KB, MacRae EJ, Mansfield W, Watt FM. Polyclonal origin and hair induction ability of dermalpapillae in neonatal and adult mouse back skin. Dev Biol. 2012;366:290-297.
517. BöhmM, LugerTA. Melanocortins in fibroblastbiology-current update and future perspective for dermatology. Exp Dermatol. 2004;13(suppl 4):16-21.
518. Böhm M, Raghunath M, Sunderkötter C, et al. Collagen metabolism is a novel target of the neuropeptide α-melanocyte-stimulating hormone. J Biol Chem. 2004;279: 6959-6966.
519. Huq S, Sharpe DT, Asaad K, Stevenson S, Tobin DJ. The hair follicle contains fibroblast subpopulations that exhibit preferential wound-healing characteristics, which can be modulated by proopiomelanocortin peptides and corticotropin-releasing factor. J Invest Dermatol. 2008;128:S45.
520. Dubicke A, Akerud A, Sennstrom M, et al. Different secretion patterns of matrix metalloproteinases and IL-8 and effect of corticotropin-releasing hormone in preterm and term cervical fibroblasts.MolHumReprod. 2008;14:641-647.
521. Slominski AT. Proopiomelanocortin signaling system is operating in mast cells. J Invest Dermatol. 2006;126: 1934-1936.
522. KawayamaT,OkamotoM,Imaoka H, Kato S,YoungHA, Hoshino T. Interleukin-18 in Pulmonary Inflammatory Diseases. J Interferon Cytokine Res. 2012;32:443-449.
523. Zbytek B, Slominski AT. Role of corticotropin-releasing hormone and its receptor in the development of dermatofibroma [conference abstract]. J Cutan Pathol. 2012;39: 101.
524. Selye H. The Mast Cells. Washington, DC: Butterworths; 1965.
525. Miniati A, Weng Z, Zhang B, Stratigos AJ, Nicolaidou E, Theoharides TC. Neuro-immuno-endocrine processes in vitiligo pathogenesis. Int J Immunopathol Pharmacol. 2012;25:1-7.
526. van den Wijngaard RM, Stanisor OI, van Diest SA, et al. Peripheral α-helical CRF (9-41) does not reverse stressinduced mast cell dependent visceral hypersensitivity in maternally separated rats. Neurogastroenterol Motil. 2012;24:274-282.e111
527. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav Immun. 1999;13:225-239.
528. Crompton R, Clifton VL, Bisits AT, Read MA, Smith R, Wright IM. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J Clin Endocrinol Metab. 2003;88:5427-5432.
529. Zhang B, Alysandratos KD, Angelidou A, et al. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol. 2011; 127:1522-1531.e8.
530. Asadi S, Theoharides TC. Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. J Neuroinflammation. 2012;9:85.
531. Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One. 2012;7:e49767.
532. Radulovic M, Dautzenberg FM, Sydow S, Radulovic J, Spiess J. Corticotropin-releasing factor receptor 1 in mouse spleen: expression after immune stimulation and identification of receptor-bearing cells. J Immunol. 1999;162: 3013-3021.
533. Venihaki M, Zhao J, Karalis KP. Corticotropin-releasing hormone deficiency results in impaired splenocyte response to lipopolysaccharide. J Neuroimmunol. 2003; 141:3-9.
534. Kiang JG, Poree L, Wei ET. Anti-inflammatory activity of corticotropin releasing factor. II. Mechanisms of action. Proc West Pharmacol Soc. 1987;30:63-65.
535. Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer. 2009;124: 1470-1477.
536. Silverman ES, Breault DT, Vallone J, et al. Corticotropinreleasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma. J Allergy Clin Immunol. 2004;114:747-754.
537. Shams K, Burden AD. Updates from the Sixth International Congress "Psoriasis: from Gene to Clinic," the Queen Elizabeth II Conference Centre, London, U.K., 1-3 December 2011. Br J Dermatol. 2012;167:757-761.
538. Tokura Y, Mori T, Hino R. Psoriasis and other Th17-mediated skin diseases. J UOEH. 2010;32:317-328.
539. Michalak-Stoma A, Pietrzak A, Szepietowski JC, Zalewska-Janowska A, Paszkowski T, Chodorowska G. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22:160-168.
540. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012; 181:8-18.
541. Vasiadi M, Therianou A, Alysandratos KD, et al. Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells. Br J Dermatol. 2012;166:1349-1352.
542. Cochrane DE, Carraway RE, Harrington K, Laudano M, Rawlings S, Feldberg RS. HMC-1 human mast cells synthesize neurotensin (NT) precursor, secrete bioactive NTlike peptide(s) and express NT receptor NTS1. Inflamm Res. 2011;60:1139-1151.
543. Harvima IT, Nilsson G. Stress, the neuroendocrine system and mast cells: current understanding of their role in psoriasis. Expert Rev Clin Immunol. 2012;8:235-241.
544. Nishioka T, Kurokawa H, Takao T, Kumon Y, Nishiya K, Hashimoto K. Differential changes of corticotropin releasing hormone(CRH)concentrations in plasma and synovial fluids of patients with rheumatoid arthritis (RA). Endocr J. 1996;43:241-247.
545. Murphy EP, McEvoy A, Conneely OM, Bresnihan B, FitzGerald O. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum. 2001;44:782-793.
546. McEvoy AN, Bresnihan B, Fitzgerald O, Murphy EP. Corticotropin-releasing hormone signaling in synovial tis-sue vascular endothelium is mediated through the cAMP/ CREB pathway. Ann NY Acad Sci. 2002;966:119-130.
547. McEvoyAN,Bresnihan B, FitzGerald O,MurphyEP. Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 α corticotropin-releasing hormone receptor. Arthritis Rheum. 2001;44:1761-1767.
548. McEvoy AN, Bresnihan B, FitzGerald O, Murphy EP. Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2004;50:1132-1145.
549. Baerwald CG, Panayi GS, Lanchbury JS. Corticotropin releasing hormone promoter region polymorphisms in rheumatoid arthritis. J Rheumatol. 1997;24:215-216.
550. Baerwald CG, Mok CC, Tickly M, et al. Corticotropin releasing hormone (CRH) promoter polymorphisms in various ethnic groups of patients with rheumatoid arthritis. Z Rheumatol. 2000;59:29-34.
551. Gonzalez-Gay MA, Hajeer AH, Garcia-Porrua C, et al. Corticotropin-releasing hormone promoter polymorphisms in patients with rheumatoid arthritis from northwest Spain. J Rheumatol. 2003;30:913-917.
552. Wagner U, Wahle M, Malysheva O, Wagner U, Hantzschel H, Baerwald C. Sequence variants of the CRH 5'-flanking region: effects on DNA-protein interactions studied by EMSA in PC12 cells. Ann NY Acad Sci. 2006;1069: 20-33.
553. Fife MS, Fisher SA, John S, et al. Multipoint linkage analysis of a candidate gene locus in rheumatoid arthritis demonstrates significant evidence of linkage and association with the corticotropin-releasing hormone genomic region. Arthritis Rheum. 2000;43:1673-1678.
554. Fife M, Steer S, Fisher S, et al. Association of familial and sporadic rheumatoid arthritis with a single corticotropinreleasing hormone genomic region (8q12.3) haplotype. Arthritis Rheum. 2002;46:75-82.
555. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17:139-140; discussion 141-160.
556. Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51:1206-1212.
557. Reimann E, Kingo K, Karelson M, et al. The mRNA expression profile of cytokines connected to the regulation of melanocyte functioning in vitiligo skin biopsy samples and peripheral blood mononuclear cells.HumImmunol. 2012; 73:393-398.
558. Yu R, Huang Y, Zhang X, Zhou Y. Potential role of neurogenic inflammatory factors in the pathogenesis of vitiligo. J Cutan Med Surg. 2012;16:230-244.
559. Graham A, Westerhof W, Thody AJ. The expression of α-MSH by melanocytes is reduced in vitiligo. Ann NY Acad Sci. 1999;885:470-473.
560. Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Aubock J. Vitiligo patients present lower plasma levels of α-melanotropin immunoreactivities. Neuropeptides. 2006;40: 177-183.
561. Kingo K, Aunin E, Karelson M, et al. Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci. 2007;48:113-122.
562. Berson JF, Theos AC, Harper DC, Tenza D, Raposo G, Marks MS. Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J Cell Biol. 2003;161:521-533.
563. +-binding capacity of epidermal furin is disrupted by H2O2-mediated oxidation in vitiligo. Endocrinology. 2008;149:1638-1645.
564. Spencer JD, Gibbons NC, Rokos H, Peters EM, Wood JM, Schallreuter KU. Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J Invest Dermatol. 2007; 127:411-420.
565. Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp Dermatol. 2005;14:143-152.
566. Lotti T, Bianchi B, Panconesi E. Neuropeptides and skin disorders. The new frontiers of neuro-endocrine-cutaneous immunology. Int J Dermatol. 1999;38:673-675.
567. Zouboulis CC, Böhm M. Neuroendocrine regulation of sebocytes-a pathogenetic link between stress and acne. Exp Dermatol. 2004;13(suppl 4):31-35.
568. Aoki E, Shibasaki T, Kawana S. Intermittent foot shock stress prolongs the telogen stage in the hair cycle of mice. Exp Dermatol. 2003;12:371-377.
569. Arck PC, Handjiski B, Peters EM, et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003;162:803-814.
570. Katayama M, Aoki E, Suzuki H, Kawana S. Foot shock stress prolongs the telogen stage of the spontaneous hair cycle in a non-depilated mouse model. Exp Dermatol. 2007;16:553-560.
571. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology. 1992;130:3378-3386.
572. Reinhold M. Relationship of stress to the development of symptoms in alopecia areata and chronic urticaria. Br Med J. 1960;1:846-849.
573. Whitlock FA. Psychophysiological aspects of skin disease. In: Rook A, ed. Major Problems in Dermatology. London, UK: WB Saunders; 1976:110-210.
574. Misery L, Rousset H. Is alopecia areata a psychosomatic disease? [in French]. Rev Med Interne. 2001;22:274-279.
575. Willemsen R, Vanderlinden J, Roseeuw D, Haentjens P. Increased history of childhood and lifetime traumatic events among adults with alopecia areata. J AmAcad Dermatol. 2009;60:388-393.
576. van der Steen P, Boezeman J, Duller P, Happle R. Can alopecia areata be triggered by emotional stress? An uncontrolled evaluation of 178 patients with extensive hair loss. Acta Derm Venereol. 1992;72:279-280.
577. Brajac I, Tkalcic M, Dragojevic DM, Gruber F. Roles of stress, stress perception and trait-anxiety in the onset and course of alopecia areata. J Dermatol. 2003;30:871-878.
578. Paus R, Arck P. Neuroendocrine perspectives in alopeciaareata: does stress play a role? J Invest Dermatol. 2009; 129:1324-1326.
579. Hordinsky MK, Ericson ME. Relationship between follicular nerve supply and alopecia. Dermatol Clin. 1996;14: 651-660.
580. Kim HS, Cho DH, Kim HJ, Lee JY, Cho BK, Park HJ. Immunoreactivity of corticotropin-releasing hormone, adrenocorticotropic hormone and α-melanocyte-stimulating hormone in alopecia areata. Exp Dermatol. 2006;15:515-522.
581. Peters EM, Liotiri S, BodóE, et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol. 2007;171:1872-1886.
582. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007; 117:2019-2027.
583. Kaprara A, Pazaitou-Panayiotou K, Chemonidou MC, et al. Distinct distribution of corticotropin releasing factor receptors in human breast cancer. Neuropeptides. 2010; 44:355-361.
584. Elias PM. Skin barrier function. Curr Allergy Asthma Rep. 2008;8:299-305.
585. Liu J, Man WY, Lv CZ, et al. Epidermal permeability barrier recovery is delayed in vitiligo-involved sites. Skin Pharmacol Physiol. 2010;23:193-200.
586. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2000;2:CD001215.
587. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol. 2008;3:569-585.
588. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet. 2012; 380:358-365.
589. Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Current advances and perspectives in the treatment of advanced melanoma. J Dtsch Dermatol Ges. 2012;10:319-325.
590. Kim MH, Cho D, Kim HJ, et al. Investigation of the corticotropin-releasing hormone-proopiomelanocortin axis in various skin tumours. Br J Dermatol. 2006;155:910-915.
591. Yuan PQ, Wu SV, TachéY. Urocortins and CRF type 2 receptor isoforms expression in the rat stomach are regulated by endotoxin: role in the modulation of delayed gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2012;303:G20-G31.
592. Theoharides A, inventor; Kos Pharmaceuticals, Inc, assignee. Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker. US patent 5855884 A. January 5, 1999.
593. Thomas HA, Ling N, Wei ET, Berree F, Cobas A, Rapoport H. Novel anti-inflammatory undecapeptides that contain anisolyated glutamic acid derivatives. J Pharmacol Exp Ther. 1993;267:1321-1326.
594. Wei ET, Thomas HA. Correlation of neuroendocrine and anti-edema activities of alanine-corticotropin-releasing factor analogs. Eur J Pharmacol. 1994;263:319-321.
595. Wei ET, Thomas HA, Price JS, Kishimoto T. [DPro5] Corticotropin-releasing factor analogs as selective agonists at corticotropin-releasing factor receptors. Eur J Pharmacol. 1996;306:161-164.
596. Wei ET, Thomas HA, Christian HC, Buckingham JC, Kishimoto T. D-amino acid-substituted analogs of corticotropin-releasing hormone (CRH) and urocortin with selective agonist activity at CRH1 and CRH2_ receptors. Peptides. 1998;19:1183-1190.
597. Gulyas J, Rivier C, Perrin M, et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci USA. 1995;92:10575-10579.
598. Iavicoli S, Lopez-Perez E, Buehring GC, Thomas HA, Wei ET, Kishimoto T. Bipolar-shape response of human neutrophils to corticotropin-releasing factor. Eur J Pharmacol. 1998;349:301-306.
599. Million M, Maillot C, Saunders P, Rivier J, Vale W, TachéY. Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats. Am J Physiol Gastrointest Liver Physiol. 2002;282: G34-G40.
600. Rivier J, Gulyas J, Kirby D, et al. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem. 2002;45: 4737-4747.
601. Rivier J, Gulyas J, Kunitake K, et al. Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist. J Med Chem. 2007;50:1668-1674.
602. Chen CY, Doong ML, Rivier JE, TachéY. Intravenous urocortin II decreases blood pressure through CRF(2) receptor in rats. Regul Pept. 2003;113:125-130.
603. Theoharides A, inventor; Kos Pharmaceuticals, Inc, assignee. 2000 Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors. US patent 6020305 A. February 1, 2000.
604. Liapakis G, Venihaki M, Margioris A, Grigoriadis D, Gkountelias K. Members of CRF family and their receptors: from past to future. Curr Med Chem. 2011;18:2583-2600.
605. Paez-Pereda M, Hausch F, Holsboer F. Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opin Investig Drugs. 2011;20:519-535.
606. Steckler T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead? Curr Top Behav Neurosci. 2010;2:415-428.
607. Ziegler CG, Krug AW, Zouboulis CC, Bornstein SR. Corticotropin releasing hormone and its function in the skin. Horm Metab Res. 2007;39:106-109.
608. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005;49:65-76.
609. Kandere-Grzybowska K, Gheorghe D, Priller J, et al. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Res. 2003;980:213-220.